65,437 trials
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) — -20.1; -58.5 Percent change — p=<0.001
Hepatitis B · Acellular Pertussis · Tetanus
Primary: Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C) — 11; 8 subjects
Pain
Primary: Verbal Pain Score — 3; 0; 0 Units on a scale — p=<0.0001
Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure
Nausea · Vomiting
Primary: Complete Response (Percentage of Patients) — 84 percentage of participants
Walking Cast Right Leg Immobilisation Effects · Aircast Right Leg Immobilisation Effects
Primary: Mean Breaking Time Measured on a Driving Car Simulator — 0.58 seconds
Urinary Incontinence
Primary: Episodes/Day — 6.6; 3.52; 8.7 number
Hypercholesterolemia
Primary: Number of Participants Reporting Adverse Events — 1; 1 Participants
Type 1 Diabetes · Type 2 Diabetes
Primary: Number of Patients With a Low Density Lipid (LDL) Value Less Than 100 mg/dL — 223; 178 Participants
Hepatitis A Virus
Primary: Antibody Response to Hepatitis A - Participants With a Serological Response — 182; 158 Participants — p=<0.001
Osteoarthritis, Knee · Pain
Primary: Percentage of Change From Baseline in WOMAC Pain Subscale Score at Week 12 — 58.3; 58.7 percentage of change
Pain · Osteoarthritis, Knee
Primary: Patient Global Rating of Pain for the Study Period (12 Weeks) — 19; 16; 26; 29 participants
Healthy
Primary: Dasatinib Pharmacokinetic (PK) Parameter: Maximum Observed Plasma Concentration (Cmax) — 65.58; 38.64 ng/mL
Brain Tumor
Primary: Global Diagnostic Preference Between the Two Exams — 22; 21; 27; 19 Contrast-enhanced Images — p=< 0.0001
Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 24 — -0.2; -1.0; 0.0 Percent Difference